# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN-TD
- Date: 1851-06-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Whitley-Adeyemi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for new patient visit for abnormal bleeding and pelvic pain: history, speculum examination and cervical biopsy, blood count and iron studies, conversion of opium tincture to measured oral morphine, an iron infusion, and a gynecologic oncology referral. **S**

## Objective

Hemoglobin: 8.4 g/dL (low); Mean cell volume: 74 fL (low); White cells: 7.8 10*3/uL; Platelets: 412 10*3/uL (high); Ferritin: 5 ng/mL (low); Creatinine: 0.68 mg/dL; ALT: 18 U/L; Albumin: 3.6 g/dL; Serum hCG: 1 m[IU]/mL; eGFR: 116 mL/min/1.73 m²; Pelvic pain, average over the past week (0 to 10): 7; PHQ-9: 8. All results are synthetic.

BP 108/68 mmHg; pulse 96 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 54 kg; BMI 19.8 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake; Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs; Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Stopped: Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain **S**
- Started: Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain **S**
- Started: Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 **S**
- Started: Senna 8.6 mg tablet, two tablets by mouth at night **S**
- Started: Polyethylene glycol 3350, 17 g in water by mouth once or twice a day **S**
- Started: Acetaminophen 500 mg tablet, two tablets by mouth three times a day **S**
- Started: Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits **S**

## Plan

- Gynecologic oncology consultation in two weeks for a friable cervical mass with bleeding and pain, biopsied today: diagnosis, staging, treatment intent, bleeding control, and pain. Guideline: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Revised FIGO staging for carcinoma of the cervix uteri (Bhatla N, et al. Int J Gynaecol Obstet 2019;145:129-135) (2018) **S**
- Stop opium tincture and change to measured oral morphine solution 5 mg every 4 hours as needed with an oral syringe, with acetaminophen, senna and polyethylene glycol, a naloxone nasal spray, a prescription monitoring check, locked storage, one prescriber, and review in two weeks. Guideline: Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (Dowell D, et al. MMWR Recomm Rep 2022;71(RR-3):1-95) (2022) **S**
- Iron deficiency anemia: ferric carboxymaltose 750 mg intravenously today and in two weeks, with a blood count at each visit and ferritin 6 to 8 weeks after the infusions. Guideline: CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026) **S**
- Blood tests: blood count, ferritin, creatinine, ALT, albumin and a pregnancy test; HIV, hepatitis B and hepatitis C tests before any cancer treatment; PHQ-9. Guideline: Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (Hwang JP, et al. J Clin Oncol 2020;38:3698-3715) (2020); Depression and Suicide Risk in Adults: Screening (2023) **S**
